|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer(ESWN 01):a prospective randomized,multicenter,open-labeled phase 3 trial显示文摘Background:The benefit of systemic treatments in esophageal squamous cell carcinoma(ESCC)which has pro-gressed after chemotherapy is still uncertain and optimal regimens based on randomized trials have not yet been established.We aimed to compare the efficacy of irinotecan plus S-1 with S-1 monotherapy in recurrent or metastatic ESCC patients who had resistance to platinum-or taxane-based chemotherapy.Methods:We conducted a prospective randomized,multicenter,open-label,phase 3 trial in 15 centers across China.Eligible patients were adults with histologically confirmed recurrent or metastatic ESCC,and were randomly assigned(ratio,1:1)to receive either irinotecan plus S-1(intravenous infusion of irinotecan[160 mg/m2]on day 1 and oral S-1[80-120 mg]on days 1-10,repeated every 14 days)or oral S-1 monotherapy(80-120 mg/day on days 1-14,repeated every 21 days)using a central computerized minimization procedure.The primary endpoint was progression-free survival(PFS).Results:Between December 23,2014 and July 25,2016,we screened 148 patients and randomly assigned 123 patients to receive either irinotecan plus S-1 regimen(n=61)or S-1 monotherapy(n=62).After a median follow-up of 29.2 months(95%confidence interval[CI]17.5-40.9 months),the median PFS was significantly longer in the irinotecan plus S-1 group than in the S-1 monotherapy group(3.8 months[95%CI 2.9-4.3 months]vs.1.7 months[95%CI 1.4-2.7 months],hazard ratio=0.58,95%CI 0.38-0.86,P=0.006).The objective response rates were 24.6%in the irinotecan plus S-1 group and 9.7%in the S-1 monotherapy group(P=0.002).The patients in the irinotecan plus S-1 group presented with increased rates of grade 3-4 leukopenia(16.4%vs.0%),neutropenia(14.8%vs.1.6%),and nausea(4.9%vs.0%).No significant difference in grade 3-4 diarrhea and no treatment-related deaths were observed in both groups.Conclusions: The combination of irinotecan with S-1 was similarly tolerable but significantly prolonged PFS compared to S-1 monotherapy as a second- or third-line treatment in patients with recurrent or metastatic ESCC. | Jing Huang Binghe Xu Ying Liu Junxing Huang Ping Lu Yi Ba Lin Wu Yuxian Bai Shu Zhang Jifeng Feng Ying Cheng Jie Li Lu Wen Xianglin Yuan Changwu Ma Chunhong Hu Qingxia Fan Xi Wang | 2019 | Cancer Communications2019，39，1： | 8 |
| 2 | An Evaluation on Transfection Efficiency of pHRE-Egr1-EGFP in Hepatocellular Carcinoma Cells Bel-7402 Mediated by PEI-MZF-NPs显示文摘 | Mei Lin Dongsheng Zhang Junxing Huang Jia Zhang Li Wang Ting Guo Li Xiao Jun Ye Lixin Zhang Daxiang Cui | 2011 | Journal of Nanomaterials2011，，： | 1 |
| 3 | The potential clinical applications of radionuclide labeled/doped gold-based nanomaterials显示文摘Radionuclides have been widely used for multimodal imaging and radioisotope therapy of cancer.Various nanomaterials have been developed as excellent nanocarriers of radionuclides for the targeted delivery into tumors,in order to minimize the unnecessary side effect and enhance the therapeutic efficacy of radiotherapy.Among those nanomaterials,gold nanomaterials with tunable morphologies,easy modification,good biological safety,and radiation sensitization capability are excellent candidates for cancer theranostics.Given the superior performance of gold-based nanomaterials in biomedicine,we summary the recent advance of radionuclide labeled/doped gold-based nanomaterials for cancer theranostics.In this review article,we will discuss the methods for labelling or doping radionuclides onto gold nanomaterials,their applications for nuclear imaging and Cerenkov luminescence(CL)imaging,as well as the radioisotope therapy of cancer,and finally the toxicity evaluation of radionuclide labeled/doped gold-based nanomaterials.We hope that our review article would provide guidance for non-experts to design the radiolabeled nanomaterials for cancer imaging guided therapy. | Wenhao Shen Hailin Zhou Teng Liu Pei Pei Junxing Huang Xuan Yi Kai Yang | 2020 | Radiation Medicine and Protection2020，1，4： | 1 |
| 4 | Distribution and depositional model of microbial carbonates in the Ordovician middle assemblage,Ordos Basin,NW China显示文摘Based on outcrop profiles,drilling cores,cast thin sections etc.,the types,microfacies combinations and distribution pattern of microbial carbonates in the Ordovician middle assemblage of the mid-eastern Ordos Basin have been systematically analyzed.The middle assemblage of Ordovician in the mid-eastern Ordos Basin has microbial carbonates formed by the calci-fication of cyanobacteria,including microbial biostromes and microbial mounds made of stromatolites,thrombolites,and on-colites.The distribution of the carbonates shows obvious“stratum-control”and“regional”characteristics.The microbial bio-stromes 2–3 m thick each are controlled by sequence cycles and sedimentary facies changes,and were mainly formed in the tidal flat environment during the depositional stages of the Ma56 and Ma55 sub-members.The microbial biostrome in the Ma55 sub-member occurring near the carbonate-evaporite transition interface in the early stage of the transgression is distributed mainly in the Mizhi subsag in the eastern part of the basin;the microbial biostrome in the Ma56 sub-member turns up near the carbonate-evoporite transition zone in ring shape in the east of the central uplift.The ancient landform had noticeable control on the distribution of microbial mounds.The microbial mounds or mound-shoal complexes developing mainly during the de-positional stages of Ma57_Ma510 sub-members are about 15–25 m thick in single layer and distributed largely in the Wushenqi-Jingbian paleouplift.The development model of the microbial carbonate rocks shows that the carbonate-evaporite lithologic transition zone and the Wushenqi-Jingbian paleouplift are favorable exploration zones of microbial carbonates in the Ordovician middle assemblages. | WEI Liubin ZHAO Junxing SU Zhongtang WEI Xinshan REN Junfeng HUANG Zhengliang WU Chunying | 2021 | Petroleum Exploration and Development2021，48，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员